Dec 20, 2024, 09:06
Mohamed Abdelaziz: Atezolizumab and Bevacizumab versus Sorafenib in Egyptian HCC patients
Mohamed Abdelaziz, National Oncology Committee member at Ministry of Health and Population in Egypt and Intern Fellow at Gustave Roussy, shared on LinkedIn:
“Thrilled to share the publication of our recent poster presented in ESMO ASIA.
Tackling the benefit of atezo/beva vs sorafenib in Egyptian HCC patients.”
Authors: A.A. Khalil, M.A. Abdelaziz, T.I. El Nahas
Further Reading:
Highlights from Day 1 of ESMO Asia 2024
Highlights from Day 2 of ESMO Asia 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 20, 2024, 09:01
Dec 20, 2024, 06:58
Dec 20, 2024, 06:17
Dec 20, 2024, 02:17
Dec 20, 2024, 02:15
Dec 20, 2024, 02:13
Dec 20, 2024, 02:10
Dec 20, 2024, 02:09